Raia Drogasil (OTCMKTS:RADLY – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05, Zacks reports. Raia Drogasil had a return on equity of 20.12% and a net margin of 2.99%.
Raia Drogasil Trading Down 5.4%
Raia Drogasil stock traded down $0.15 during trading hours on Tuesday, hitting $2.70. The company had a trading volume of 25,105 shares, compared to its average volume of 34,591. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.58 and a current ratio of 1.41. The firm has a market cap of $3.55 billion and a P/E ratio of 16.76. The company has a 50-day moving average price of $3.72 and a two-hundred day moving average price of $4.07. Raia Drogasil has a 1 year low of $2.63 and a 1 year high of $5.34.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group upgraded Raia Drogasil to a “buy” rating and set a $5.20 target price on the stock in a research note on Sunday, October 18th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Raia Drogasil currently has an average rating of “Moderate Buy” and a consensus target price of $5.20.
View Our Latest Report on Raia Drogasil
Raia Drogasil Company Profile
Raia Drogasil, now operating under the name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a network of pharmacies offering prescription medicines, over-the-counter drugs, vitamins, personal care products, beauty items and other health-related merchandise.
The company also provides digital purchasing and delivery services through its online channels, supporting customers with prescription fulfillment, health products and related services. Its operations include pharmacy-based healthcare initiatives designed to complement its retail business and improve access to everyday healthcare.
RD Saúde was created in 2011 through the merger of Drogasil and Droga Raia, two established Brazilian pharmacy chains.
Read More
- Five stocks we like better than Raia Drogasil
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
